ENTITY
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (1349 HK)

139
Analysis
Health Care • China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical is primarily engaged in the innovative research and development, production, and marketing of biopharmaceuticals. The company offers a range of products including photodynamic technology drugs like aminolevulinic acid hydrochloride and hemoporfin, doxorubicin liposome under the Libord brand, genetic engineering drugs, and oral solid preparation technology drugs. It is headquartered in Zhangjiang Hi-Tech Park, Pudong, Shanghai, China, and was established in November 1996.
more
•05 Jan 2021 09:51

Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape

This article summarized the insights on major products of Bio-Thera Solutions in the pipeline and related competitive landscape with other key...

Logo
548 Views
Share
bullish•Ant Group
•29 Oct 2020 09:36

Ant Group IPO:Ā  STAR Market Trading Stats, A/H Spread

Ant Group aims to raise around USD 35bn via a dual listing on HKEX and STAR board. In this note, we will look at past STAR market IPOs, their...

Share
•28 Sep 2020 16:36

Evergrande Auto (708 HK): EGM Ahead Of Star Market Listing

This week in StubWorld ... Three days after raising HK$4bn via a top-up placement,Ā Evergrande Auto (708 HK)Ā ("EA") also officially known...

Logo
447 Views
Share
bearish•Ascletis Pharma
•22 Jul 2018 16:09

Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation

Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...

Logo
1k Views
Share
x